XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2024
Accounting Policies [Abstract]  
Schedule of Concentration of Risk, by Risk Factor and Significant Payer For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:
 
 Revenue
 Three Months Ended
June 30,
Six Months Ended
June 30,
 2024202320242023
Medicare Advantage25 %19 %21 %18 %
Medicare23 %29 %25 %34 %
Blue Shield11 %10 %**
*Less than 10%.

Accounts Receivable, Net
 June 30, 2024December 31, 2023
Medicare50 %42 %
Medicare Advantage10 %16 %
*Less than 10%.
Schedule of Disaggregation of Revenue
The following table includes the Company's revenues as disaggregated by payor and customer category (in thousands):
 
 Three Months Ended June 30,Six Months Ended June 30,
 2024202320242023
Revenue:
Commercial$8,672 $7,484 $15,535 $11,699 
Government3,457 4,189 7,643 8,615 
Client(1)2,910 2,273 6,194 4,680 
Other(2)25 191 107 373 
Total revenue$15,064 $14,137 $29,479 $25,367 
(1)Includes hospitals, other laboratories, etc.
(2)Includes patient self-pay.
Schedule of Cash and Cash Equivalents
Cash, cash equivalents, and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):
 
 June 30, 2024December 31, 2023
Cash and cash equivalents$24,479 $36,493 
Restricted cash200 200 
$24,679 $36,693 
Schedule of Restricted Cash and Cash Equivalents
Cash, cash equivalents, and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):
 
 June 30, 2024December 31, 2023
Cash and cash equivalents$24,479 $36,493 
Restricted cash200 200 
$24,679 $36,693 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):
 
 June 30, 2024June 30, 2023
Warrants to purchase common stock409,108 409,108 
Common stock options817,046 994,526 
Restricted stock units1,679,469 1,598,578 
Employee stock purchase plan38,299 60,719 
Total2,943,922 3,062,931